Abstract 687P
Background
Molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. We aimed to assess the clinical characteristics and molecular profiles of patients who were screened over a 3-year period (2022-2024).
Methods
This retrospective study included patients with advanced NSCLC who were routinely screened for actionable mutations (either a limited 9 gene or 12 gene panel or full NGS) in the host institution or CAP-certified laboratories. We analysed the frequency of nine actionable genomic alterations that were routinely screened from 10 comprehensive cancer centres in South India.
Results
We screened 922 patients, out of whom 37 (4%) had insufficient tumour tissue for NGS. Thus, 885 patients were included in the final analysis. The median age was 65 years [range 18–98 years]. The majority were males; 557 (62.9%). The smoking status was unavailable for 150 (16.9%) patients, and among the remaining 735, 573 (77.9%) were non-smokers. The histopathology was adenocarcinoma in 684 (77.3%) patients and 53 (6%) had squamous cell carcinoma. An actionable genomic abnormality was detected in 490 (55.3%) patients. EGFR mutations were detected in 330 (37.3%), KRAS (G12C) mutations in 44 (4.9%), HER2 mutations in 23 (2.6 %), BRAF mutations in 27 (3.1 %), MET Exon 14 skipping mutation in 16 (1.8 %), ALK rearrangements in 79 (8.9 %), Ros-1 positivity in 17 (1.9 %), RET positivity in 12 (1.4%), and NTRK in one patient. Co-alterations were detected in 59 (6.6%) patients. The recommended targeted therapy was administered to 365 (67%) patients.
Conclusions
This is the first retrospective study to comprehensively characterise all the actionable genomic landscape of NSCLC in India. There was a significant difference in the genomic alterations seen in our patients compared to other centres from India and South Asia, South East Asia, and the West. Actionable alterations were identified in 490 (55.3%) patients, and EGFR was the most common oncogenic driver alteration (37.3%), followed by ALK (8.9%) and KRAS -G12C (4.9%), and our study revealed a lower prevalence of patients with tumours harbouring MET, Ros-1, RET, and NTRK fusions compared with other studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.